Reply
Toshimi Kaido, Ahmed Hammad, Shinji Uemoto – 24 April 2015
The (II)logic of iron reduction therapy for steatohepatitis
Paul C. Adams – 24 April 2015
Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation
François Faitot, Marc‐Antoine Allard, Gabriella Pittau, Oriana Ciacio, René Adam, Denis Castaing, Antonio Sa Cunha, Gilles Pelletier, Daniel Cherqui, Didier Samuel, Eric Vibert – 24 April 2015 – Liver transplantation (LT) is the best curative treatment for early hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the current shortage of organs causes prolonged waiting times and poorer intention‐to‐treat (ITT) survival (i.e., after listing) owing to tumor progression and dropout.
Natural killer T cells: Novel players in biliary disease?
Marcial Sebode, Christoph Schramm – 24 April 2015
Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
Chih‐Lin Lin, Jia‐Horng Kao – 24 April 2015
Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study
Lisa B. VanWagner, Jane E. Wilcox, Laura A. Colangelo, Donald M. Lloyd‐Jones, J. Jeffrey Carr, Joao A. Lima, Cora E. Lewis, Mary E. Rinella, Sanjiv J. Shah – 24 April 2015 – Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity‐related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown.
Cell‐type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma
Nikolai A. Timchenko – 24 April 2015
Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation
François Faitot, Marc‐Antoine Allard, Gabriella Pittau, Oriana Ciacio, René Adam, Denis Castaing, Antonio Sa Cunha, Gilles Pelletier, Daniel Cherqui, Didier Samuel, Eric Vibert – 24 April 2015 – Liver transplantation (LT) is the best curative treatment for early hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the current shortage of organs causes prolonged waiting times and poorer intention‐to‐treat (ITT) survival (i.e., after listing) owing to tumor progression and dropout.
Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study
Lisa B. VanWagner, Jane E. Wilcox, Laura A. Colangelo, Donald M. Lloyd‐Jones, J. Jeffrey Carr, Joao A. Lima, Cora E. Lewis, Mary E. Rinella, Sanjiv J. Shah – 24 April 2015 – Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity‐related conditions with high cardiovascular mortality. Whether NAFLD is independently associated with subclinical myocardial remodeling or dysfunction among the general population is unknown.
Myeloid cells in hepatocellular carcinoma
Shanshan Wan, Ning Kuo, Ilona Kryczek, Weiping Zou, Theodore H. Welling – 24 April 2015 – Hepatocellular carcinoma (HCC) is highly associated with inflammation. Myeloid cells, including tumor‐associated macrophages and myeloid‐derived suppressor cells, are abundant in the HCC microenvironment and are often associated with poor prognosis. Myeloid cells in HCC play a vital role in supporting tumor initiation, progression, angiogenesis, metastasis, and therapeutic resistance.